Author information

)]TJ 0 Tc T* ( )Tj 0.0003 Tc -0.0003 Tw T* [(The safety and efficacy of com)8.1 (binations of)]TJ 0.0006 Tc -0.0006 Tw 17.16 0 Td [( VIAGRA with other treatm)8.4 (e)-0.6 (nts for erectile )]TJ 0.0005 Tc -0.0005 Tw -17.16 -1.165 Td (dysfunction have not been studied. Therefore, th)Tj 0.0006 Tc -0.0006 Tw 19.405 0 Td [(e use of such com)8.4 (b)0.6 (inations is not recom)8.4 (m)8.4 (e)-0.6 (nded. )]TJ 0 Tc 0 Tw -19.405 -1.165 Td ( )Tj 0.0004 Tc -0.0004 Tw T* [(In hum)8.2 (ans, VIAGRA has no effect on bleeding tim)8.2 (e when taken alone or with aspirin. )]TJ 0.0002 Tc -0.0002 Tw 17.72 0 Td [(The com)8 (bination of heparin and VIAGRA had an )]TJ 0.001 Tc -0.001 Tw -17.72 -1.165 Td [(additive ef)4 (f)4 (ect on bleeding tim)8.8 (e in the anesthetized rabbit, but this interaction has not been )]TJ 0.0006 Tc -0.0006 Tw T* [(studied in hum)8.4 (ans. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0007 Tc -0.0007 Tw 0 -1.18 TD (Information for Patients )Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.155 TD (Physicians should discuss with patients the c)Tj 0.0004 Tc -0.0004 Tw (ontraindication of VIAGRA with regular and/or )Tj 0.0011 Tc -0.0011 Tw 0 -1.165 TD [(interm)8.9 (ittent use of)4.1 ( organic nitrates.

Sildenafil Citrate

)]TJ 0 Tc 0 Tw T* ( )Tj 0.0006 Tc -0.0006 Tw T* [(Physicians should advise patients of the potential for VIAGRA to augm)8.4 (ent the blood pressure )]TJ T* [(lowering effect of alpha-blockers and anti-hypertensive m)8.5 (edications. Concom)8.5 (itant )]TJ 0.0005 Tc -0.0005 Tw T* [(adm)8.3 (i)-1.7 (nistration of VIAGRA and an alpha-blocker m)8.3 (a)-0.7 (y lead to sym)8.3 (p)0.5 (tom)8.3 (a)-0.7 (tic sildenafil film tablet hypotension in som)8.3 (e)-0.7 ( )]TJ 0.0006 Tc -0.0006 Tw T* [(patients. Therefore, when VIAGRA is co-adm)8.4 (inistered with alpha-blockers, patients should be )]TJ 0.001 Tc -0.001 Tw T* (stable on alpha-blocker therapy prior to in)Tj 0.0001 Tc -0.0001 Tw 16.865 0 Td [(itiating VIAGRA treatm)7.9 (e)-1.1 (nt and VIAGRA should be )]TJ 0.001 Tc -0.001 Tw -16.865 -1.165 Td (initiated at the lowest dose. )Tj 0 Tc 0 Tw T* ( )Tj 0.0009 Tc -0.0009 Tw T* (Physicians should discuss with patients the potential cardiac risk of se\ xual activity in patients )Tj 0.0008 Tc -0.0008 Tw T* [(with preexisting cardiovascular risk factors. Patients who experience sy\ m)8.6 (p)0.8 (tom)8.6 (s \(e.g., angina )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 308 0 obj <>>>/Resources 331 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. For current labeling information, please visit endstream endobj 325 0 obj <> endobj 329 0 obj <> endobj 324 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 311 0 obj <> endobj 306 0 obj <>stream q 1 0 0 1 -8.008606 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.008606 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.9914 47.6228 Tm ( )Tj 19 -0.005 Td (12)Tj 0.0008 Tc -0.0008 Tw -19 54.94 Td [(- In those patients already taking an optim)8.6 (ized dose of a PDE5 inhibitor, alpha-blocker therapy )]TJ 0 -1.165 TD [(should be initiated at the lowest dose. Stepwise increase in alpha-block\ er dose m)8.6 (ay be associated )]TJ 0.0005 Tc -0.0005 Tw T* (with further lowering of blood pressure when taking a PDE5 inhibitor. )Tj T* [(- Safety of com)8.3 (b)0.5 (ined use of PDE5 inhibitors and alpha-blockers m)8.3 (a)-0.7 (y be affected by other )]TJ 0.0009 Tc -0.0009 Tw T* [(variables, including intravascular volum)8.7 (e depletion and other anti-hypertensive drugs.

Product	Dosage	Quantity + Bonus	Price
Kamagra	100mg	360 + 6 Pills	839.95€ 799.95€
Viagra Generic	100mg	360 + 10 Pills	330.21€ 314.49€
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€
Kamagra Soft Tabs	100mg	120 + 6 Pills	311.78€ 296.93€
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€
Viagra Generic	200mg	120 + 8 Pills	204.80€ 195.05€
Viagra Generic	150mg	60 + 4 Pills	111.25€ 105.95€
Kamagra Soft Tabs	100mg	12 Pills	57.55€ 54.81€
Viagra Generic	100mg	90 + 6 Pills	129.02€ 122.88€
Kamagra Oral Jelly	100mg	63 + 7 Sachets	224.18€ 213.50€
Viagra Generic	50mg	20 Pills	40.52€ 38.59€
Viagra Generic	200mg	90 + 6 Pills	170.79€ 162.66€
Viagra Generic	100mg	180 + 8 Pills	199.37€ 189.88€
Viagra Generic	150mg	90 + 6 Pills	147.18€ 140.17€
Kamagra	100mg	60 + 4 Pills	201.34€ 191.75€

Is generic medication less effective than brand-name medication?

What’s the difference between sildenafil and Viagra?

)]TJ 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(Patients on m)8.8 (u)1 (ltiple antihypertensive m)8.8 (edications were included in the pivotal clinical trials for )]TJ 0.0004 Tc -0.0004 Tw T* (VIAGRA. In a separate drug interaction study, wh)Tj 0.0002 Tc -0.0002 Tw 20.21 0 Td [(en am)8 (lodipine, 5 m)8 (g or 10 m)8 (g, and VIAGRA, )]TJ 0.0008 Tc -0.0008 Tw -20.21 -1.165 Td [(100 m)8.6 (g)0.8 ( were orally adm)8.6 (i)-1.4 (nistered concom)8.6 (itantly to hypertensive patients m)8.6 (ean additional blood )]TJ 0.0007 Tc -0.0007 Tw 0 -1.18 TD [(pressure reduction of 8 m)8.5 (m)8.5 (H)2.9 (g systolic and 7 m)8.5 (m)8.5 (H)2.9 (g diastolic were noted \(see )]TJ /TT1 1 Tf -0.0006 Tc 0 Tw 31.42 0 Td (Drug )Tj 0.0006 Tc -31.42 -1.18 Td (Interactions)Tj /TT0 1 Tf 0.001 Tc 5.175 0 Td (\). )Tj 0 Tc -5.175 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD (The safety of VIAGRA is unknown in patients with bleeding disorders and \ patients with active )Tj 0.001 Tc -0.001 Tw T* (peptic ulceration. )Tj 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(VIAGRA should be used with caution in patients with anatom)8.3 (ical deform)8.3 (ation of the penis \(such )]TJ 0.0008 Tc -0.0008 Tw T* (as angulation, cavernosal fibrosis or Peyronie\222s disease\), or in pat\ ients who have conditions )Tj 0.0009 Tc -0.0009 Tw T* [(which m)8.7 (ay predispose them)8.7 ( to priapism)8.7 ( \(such as sickle cell anem)8.7 (ia, m)8.7 (u)0.9 (ltiple m)8.7 (y)0.9 (elom)8.7 (a, or )]TJ 0 Tw T* [(leukem)8.7 (i)-1.3 (a\).

Overdose/Missed Dose

To decrease the chance of )]TJ 0.0009 Tc -0.0009 Tw T* [(adverse events in patients taking ritonavir, a decrease in sildenafil do\ sage is recom)8.7 (m)8.7 (ended \(see )]TJ /TT2 1 Tf -0.0006 Tc 0.0006 Tw 0 -1.18 TD (Drug Interactions, ADVERSE REACTIONS )Tj /TT0 1 Tf 0.0003 Tc 0 Tw 19.345 0 Td (and )Tj /TT2 1 Tf -0.0009 Tc 0.0009 Tw (DOSAGE AND ADMINISTRATION)Tj /TT0 1 Tf 0.001 Tc 0 Tw 17.675 0 Td (\). )Tj 0 Tc -37.02 -1.165 Td ( )Tj 0 -1.165 TD ( )Tj /TT2 1 Tf -0.0013 Tc 15.6213 Tw 0 -1.18 TD ( PRECAUTIONS )Tj 0.0011 Tc 0 Tw 0 -1.17 TD (General )Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.155 TD [(The evaluation of erectile dysfunction should include a determ)8.6 (ination of potential underlying )]TJ 0 -1.165 TD [(causes and the identification of appropriate treatm)8.6 (ent following a com)8.6 (p)0.8 (lete m)8.6 (edical assessm)8.6 (ent. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0006 Tc -0.0006 Tw T* [(Before prescribing VIAGRA, it is im)8.4 (portant to note the following: )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Caution is advised when Phosphodiesterase Type 5 \(PDE5\) inhibitors are\ co-adm)8.5 (inistered with )]TJ 0.0005 Tc -0.0005 Tw T* (alpha-blockers.

Dosage forms

Sildenafil white is often sold as small, round, white tablets.
It is available in various formulations, including sublingual and capsules.
The drug increases cGMP levels, leading to smooth muscle relaxation.
Generic sildenafil is usually cheaper than brand-name Viagra.
Erectile dysfunction can be caused by physical or mental health issues.
Misusing sildenafil white can result in priapism, a painful erection lasting hours.
Some formulations come with flavoring to improve taste.
Patient education about correct use is key to safety and effectiveness.
Sildenafil white does not protect against sexually transmitted infections.
It is important to avoid taking more than the recommended dose.
Long-term safety data is still being studied, but generally considered safe when used properly.

)]TJ 0 Tc 0 Tw -19.405 -1.165 Td ( )Tj 0.0004 Tc -0.0004 Tw T* [(In hum)8.2 (ans, VIAGRA has no effect on bleeding tim)8.2 (e when taken alone or with aspirin.

7.2 Alpha-blockers

) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 313 0 obj <>>>/Resources 327 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 327 0 obj <> endobj 328 0 obj <> endobj 326 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 325 0 obj <> endobj 329 0 obj <> endobj 324 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 311 0 obj <> endobj 306 0 obj <>stream q 1 0 0 1 -8.008606 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.008606 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.9914 47.6228 Tm ( )Tj 19 -0.005 Td (12)Tj 0.0008 Tc -0.0008 Tw -19 54.94 Td [(- In those patients already taking an optim)8.6 (ized dose of a PDE5 inhibitor, alpha-blocker therapy )]TJ 0 -1.165 TD [(should be initiated at the lowest dose. Stepwise increase in alpha-block\ er dose m)8.6 (ay be associated )]TJ 0.0005 Tc -0.0005 Tw T* (with further lowering of blood pressure when taking a PDE5 inhibitor. )Tj T* [(- Safety of com)8.3 (b)0.5 (ined use of PDE5 inhibitors and alpha-blockers m)8.3 (a)-0.7 (y be affected by other )]TJ 0.0009 Tc -0.0009 Tw T* [(variables, including intravascular volum)8.7 (e depletion and other anti-hypertensive drugs.

Drug Interactions

)]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Viagra has system)8.5 (ic vasodilatory properties and m)8.5 (ay augm)8.5 (ent the blood pressure lowering effect )]TJ 0.0009 Tc -0.0009 Tw T* [(of other anti-hypertensive m)8.7 (edications. )]TJ 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(Patients on m)8.8 (u)1 (ltiple antihypertensive m)8.8 (edications were included in the pivotal clinical trials for )]TJ 0.0004 Tc -0.0004 Tw T* (VIAGRA. In a separate drug interaction study, wh)Tj 0.0002 Tc -0.0002 Tw 20.21 0 Td [(en am)8 (lodipine, 5 m)8 (g or 10 m)8 (g, and VIAGRA, )]TJ 0.0008 Tc -0.0008 Tw -20.21 -1.165 Td [(100 m)8.6 (g)0.8 ( were orally adm)8.6 (i)-1.4 (nistered concom)8.6 (itantly to hypertensive patients m)8.6 (ean additional blood )]TJ 0.0007 Tc -0.0007 Tw 0 -1.18 TD [(pressure reduction of 8 m)8.5 (m)8.5 (H)2.9 (g systolic and 7 m)8.5 (m)8.5 (H)2.9 (g diastolic were noted \(see )]TJ /TT1 1 Tf -0.0006 Tc 0 Tw 31.42 0 Td (Drug )Tj 0.0006 Tc -31.42 -1.18 Td (Interactions)Tj /TT0 1 Tf 0.001 Tc 5.175 0 Td (\). )Tj 0 Tc -5.175 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD (The safety of VIAGRA is unknown in patients with bleeding disorders and \ patients with active )Tj 0.001 Tc -0.001 Tw T* (peptic ulceration. )Tj 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(VIAGRA should be used with caution in patients with anatom)8.3 (ical deform)8.3 (ation of the penis \(such )]TJ 0.0008 Tc -0.0008 Tw T* (as angulation, cavernosal fibrosis or Peyronie\222s disease\), or in pat\ ients who have conditions )Tj 0.0009 Tc -0.0009 Tw T* [(which m)8.7 (ay predispose them)8.7 ( to priapism)8.7 ( \(such as sickle cell anem)8.7 (ia, m)8.7 (u)0.9 (ltiple m)8.7 (y)0.9 (elom)8.7 (a, or )]TJ 0 Tw T* [(leukem)8.7 (i)-1.3 (a\). )]TJ 0.0002 Tc -0.0002 Tw 17.72 0 Td [(The com)8 (bination of heparin and VIAGRA had an )]TJ 0.001 Tc -0.001 Tw -17.72 -1.165 Td [(additive ef)4 (f)4 (ect on bleeding tim)8.8 (e in the anesthetized rabbit, but this interaction has not been )]TJ 0.0006 Tc -0.0006 Tw T* [(studied in hum)8.4 (ans. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0007 Tc -0.0007 Tw 0 -1.18 TD (Information for Patients )Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.155 TD (Physicians should discuss with patients the c)Tj 0.0004 Tc -0.0004 Tw (ontraindication of VIAGRA with regular and/or )Tj 0.0011 Tc -0.0011 Tw 0 -1.165 TD [(interm)8.9 (ittent use of)4.1 ( organic nitrates.

Sildenafil white is sometimes called the "blue pill" in popular culture.
It remains one of the most prescribed medications for ED worldwide.
Some individuals purchase sildenafil white without a prescription, which can be risky.
Derived from a scientific discovery initially aimed at heart treatment.
Viagra was the first brand to market sildenafil for ED.
The medication can cause side effects like dizziness and upset stomach.
Elderly patients should be cautious due to increased risk of side effects.
Regular medical check-ups are recommended for long-term sildenafil users.
Lifestyle changes, such as exercise and diet, can enhance treatment results.
The medication is typically taken on an empty stomach for quicker effect.
Research continues into new formulations and delivery methods for sildenafil

Sildenafil white is a common name for the generic version of Viagra.
It is used to treat erectile dysfunction in men.
Sildenafil white is known for its rapid onset of action.
The medication works by enhancing blood flow to the penis.
It is typically taken about 30 to 60 minutes before sexual activity.
Sildenafil white is available in various doses, usually 25mg, 50mg, and 100mg.
The drug should not be used with nitrate medications to avoid dangerous interactions.
Common side effects include headache, flushing, and nasal congestion.
It is important to follow dosage instructions provided by a healthcare provider.
Sildenafil white can cause low blood pressure in some users.
Store sildenafil white in a cool, dry place, away from direct sunlight.

Concom)8.5 (itant )]TJ 0.0005 Tc -0.0005 Tw T* [(adm)8.3 (i)-1.7 (nistration of VIAGRA and an alpha-blocker m)8.3 (a)-0.7 (y lead to sym)8.3 (p)0.5 (tom)8.3 (a)-0.7 (tic sildenafil film tablet hypotension in som)8.3 (e)-0.7 ( )]TJ 0.0006 Tc -0.0006 Tw T* [(patients. Therefore, when VIAGRA is co-adm)8.4 (inistered with alpha-blockers, patients should be )]TJ 0.001 Tc -0.001 Tw T* (stable on alpha-blocker therapy prior to in)Tj 0.0001 Tc -0.0001 Tw 16.865 0 Td [(itiating VIAGRA treatm)7.9 (e)-1.1 (nt and VIAGRA should be )]TJ 0.001 Tc -0.001 Tw -16.865 -1.165 Td (initiated at the lowest dose. )Tj 0 Tc 0 Tw T* ( )Tj 0.0009 Tc -0.0009 Tw T* (Physicians should discuss with patients the potential cardiac risk of se\ xual activity in patients )Tj 0.0008 Tc -0.0008 Tw T* [(with preexisting cardiovascular risk factors.

Further information

) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 309 0 obj <>>>/Resources 333 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 333 0 obj <> endobj 334 0 obj <> endobj 332 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 331 0 obj <> endobj 335 0 obj <> endobj 330 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 307 0 obj <> endobj 302 0 obj <>stream q 1 0 0 1 -8.141602 -1.487244 cm 0 0 612 792 re W n 1 0 0 1 8.141602 1.487244 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.8584 48.0128 Tm ( )Tj 19 -0.005 Td (11)Tj /C2_0 1 Tf -19 54.875 Td <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw 1.04 0 Td [(Patients with resting hypotension \(BP )-3.4 (<90/50\) or hypertension \(BP >170/110\); )]TJ 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf 0 -1.23 TD <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td (Patients with cardiac failure or coronary artery disease causing unstabl\ e angina; )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf T* <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td [(Patients with retinitis pigm)8.7 (entosa \(a m)8.7 (i)-1.3 (nority of)3.9 ( these patients have genetic disorders of)3.9 ( )]TJ 0 -1.165 TD (retinal phosphodiesterases\). )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj 0.0008 Tc -0.0008 Tw T* [(Prolonged erection greater than 4 hours and priapism)6.7 ( \(painful erections greater than 6 hours in )]TJ 0.0006 Tc -0.0006 Tw T* [(duration\) have been reported infrequently since m)8.4 (a)-0.6 (rket approval of VIAGRA. In the event of an )]TJ 0.0009 Tc -0.0009 Tw T* [(erection that persists longer than 4 hours, the patient should seek im)8.7 (m)8.7 (ediate m)8.7 (edical assistance.

Kamagra Polo

)]TJ 0.0008 Tc -0.0008 Tw T* [(If priapism)8.6 ( is not treated im)8.6 (m)8.6 (ediately, penile tissue dam)8.6 (age and perm)8.6 (anent loss of potency could )]TJ 0.0012 Tc 0 Tw T* (result. If VIAGRA is prescribed to patients )Tj 0.0006 Tc -0.0006 Tw -11.49 -1.165 Td [(taking ritonavir, caution should be used. Data from)5.2 ( subjects exposed to high system)8.5 (ic levels of )]TJ 0.001 Tc -0.001 Tw 0 -1.165 TD [(sildenafil are lim)8.8 (ited. Visual disturbances occurre)]TJ 0.0008 Tc -0.0008 Tw 19.92 0 Td [(d m)8.6 (o)0.8 (re com)8.6 (m)8.6 (only at higher levels of sildenafil )]TJ 0.0006 Tc -0.0006 Tw -19.92 -1.165 Td [(exposure. Decreased blood pressure, syncope, a)-0.6 (nd prolonged erection were reported in som)8.5 (e )]TJ T* [(healthy volunteers exposed to high doses of sildenafil \(200-800 m)8.4 (g)0.6 (\). Patients who experience sy\ m)8.6 (p)0.8 (tom)8.6 (s \(e.g., angina )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 308 0 obj <>>>/Resources 331 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 309 0 obj <>>>/Resources 333 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 333 0 obj <> endobj 334 0 obj <> endobj 332 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 331 0 obj <> endobj 335 0 obj <> endobj 330 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 307 0 obj <> endobj 302 0 obj <>stream q 1 0 0 1 -8.141602 -1.487244 cm 0 0 612 792 re W n 1 0 0 1 8.141602 1.487244 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.8584 48.0128 Tm ( )Tj 19 -0.005 Td (11)Tj /C2_0 1 Tf -19 54.875 Td <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw 1.04 0 Td [(Patients with resting hypotension \(BP )-3.4 (<90/50\) or hypertension \(BP >170/110\); )]TJ 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf 0 -1.23 TD <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td (Patients with cardiac failure or coronary artery disease causing unstabl\ e angina; )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf T* <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td [(Patients with retinitis pigm)8.7 (entosa \(a m)8.7 (i)-1.3 (nority of)3.9 ( these patients have genetic disorders of)3.9 ( )]TJ 0 -1.165 TD (retinal phosphodiesterases\). )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj 0.0008 Tc -0.0008 Tw T* [(Prolonged erection greater than 4 hours and priapism)6.7 ( \(painful erections greater than 6 hours in )]TJ 0.0006 Tc -0.0006 Tw T* [(duration\) have been reported infrequently since m)8.4 (a)-0.6 (rket approval of VIAGRA.

Chemical synthesis

In the event of an )]TJ 0.0009 Tc -0.0009 Tw T* [(erection that persists longer than 4 hours, the patient should seek im)8.7 (m)8.7 (ediate m)8.7 (edical assistance.

Sildenafil helps men with erectile dysfunction get and maintain an erection for sexual intercourse. It usually starts to work within 30-60 minutes.

Sildenafil side effects

Drug Type	Effect on Sildenafil White	Notes
Nitrates	Potentiate hypotensive effects	Contraindicated
CYP3A4 Inhibitors	Increase sildenafil levels, risk of side effects	Use lower dose if necessary
Alpha-blockers	Risk of hypotension	Monitor blood pressure
P450 Enzyme Inducers	Decrease effectiveness	Monitor and adjust dosage

Decreased blood pressure, syncope, a)-0.6 (nd prolonged erection were reported in som)8.5 (e )]TJ T* [(healthy volunteers exposed to high doses of sildenafil \(200-800 m)8.4 (g)0.6 (\).

Parameter	Value	Notes
Absorption Rate	Rapid, 30-60 minutes	Peak concentration in 60 min
Bioavailability	Approximately 40%	Varies by individual
Half-life	About 4 hours	Elimination from body
Metabolism	Liver via CYP3A4 enzyme	Major pathway
Excretion	Mainly via feces, some in urine	After metabolism

11 DESCRIPTION